Maze Therapeutics, Inc. 8-K

What Happened
Maze Therapeutics, Inc. (MAZE) filed a Form 8-K (Item 5.02) on May 22, 2026 reporting that Amy Bachrodt gave notice on May 18, 2026 that she will resign as Senior Vice President, Finance effective June 1, 2026. The filing states the resignation was not due to any disagreement with the company regarding operations, policies, practices, or financial reporting. Following Bachrodt’s departure, Chief Financial Officer Misbah Tahir will be designated as the company’s principal accounting officer.

Key Details

• Filing: Form 8-K filed May 22, 2026 (Item 5.02: Departure/Election of Officers/Directors).
• Resignation notice date: May 18, 2026; effective date: June 1, 2026.
• Officer leaving: Amy Bachrodt, Senior Vice President, Finance.
• Successor for accounting role: Misbah Tahir, Chief Financial Officer, will be designated principal accounting officer.
• Company statement: Resignation not due to any disagreement over company operations, policies, practices, or financial reporting.

Why It Matters
This is an executive-level change affecting the company’s finance function and accounting leadership. For investors, the key facts are the timely designation of the CFO as principal accounting officer (which maintains continuity in financial oversight) and the company’s affirmative statement that the departure was not related to financial reporting disagreements. Monitor future disclosures for any additional interim staffing or changes to financial reporting responsibilities.